-+ 0.00%
-+ 0.00%
-+ 0.00%

Galectin Therapeutics Q4 EPS $(0.08) Beats $(0.11) Estimate

Benzinga·03/31/2026 14:19:59
Listen to the news
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 57.89 percent increase over losses of $(0.19) per share from the same period last year.